Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 5/20 | 0.59 |
| ▸ | ARG1 | P05089 | 4/20 | 0.59 |
| ▸ | GGT1 | P19440 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28391632 | 1.00 | ARG2 (0.59) | ARG2ARG1GGT1BLMCYP4F2 | |
| SCHEMBL28396676 | 1.00 | ARG2 (0.59) | ARG2ARG1GGT1BLMCYP4F2 | |
| SCHEMBL498228 | 0.98 | ARG2 (0.62) | ARG2ARG1GGT1BLMCYP4F2 | |
| SCHEMBL21498188 | 0.96 | ARG2 (0.60) | ARG2ARG1GGT1BLMCYP4F2 | |
| SCHEMBL8688802 | 0.87 | ARG2 (0.72) | ARG2ARG1GGT1BLMFFAR1 | |
| SCHEMBL13774924 | 0.85 | — | — | |
| SCHEMBL9615913 | 0.85 | — | — | |
| SCHEMBL8687592 | 0.82 | GGT1 (0.65) | ARG2ARG1GGT1BLMMEN1 | |
| SCHEMBL18124758 | 0.81 | ARG1 (0.59) | ARG2ARG1GGT1BLMMEN1 | |
| SCHEMBL162337 | 0.81 | ARG1 (0.59) | ARG2ARG1GGT1BLMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138335-B | Preparation method of optically active 2-methylproline | 山东四环药业股份有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-111138335-A | Preparation method of optically active 2-methylproline | 山东四环药业股份有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-111138335-B | Preparation method of optically active 2-methylproline | 山东四环药业股份有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-111138335-B | Preparation method of optically active 2-methylproline | 山东四环药业股份有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-111138335-A | Preparation method of optically active 2-methylproline | 山东四环药业股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-111138335-A | Preparation method of optically active 2-methylproline | 山东四环药业股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9629789-B2 | Rosacea treatments using polymetal complexes | OBAGI MEDICAL PRODUCTS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-5536750-A | ANTITUMOR | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | disclosed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0668856-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE. | MERCK & CO INC (US) | 1995-11-22 | — | — | EP | disclosed |
| EP-0668856-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1995-08-30 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5326773-A | Prodrug enzyme inhibitors | MERCK & CO., INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1994010137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315785-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | ARG2 4411/4885ARG1 4390/4885GGT1 1221/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | ARG2 4411/4885ARG1 4390/4885GGT1 1221/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | ARG2 4411/4885ARG1 4390/4885GGT1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.